find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
33
Clinical Trials
Multiple Myeloma
Phase III
Active
nct/study# NA / 64007957MMY3001
A Phase 3 Randomized Study Comparing Teclistamab In Combination With Daratumumab SC (Tecdara) Versus Daratumumab SC, Pomalidomide And Dexamethasone (Dpd) Or Daratumumab SC, Bortezomib, And Dexamethasone (Dvd) In Participants With Relapsed Or Refractory Multiple Myeloma
Learn More
Multiple Myeloma
NA
Active
nct/study# NA / KARYOPHARM-RWE
Treatment Patterns And Adverse Event Management In Patients Treated With Selinexor In Combination With Other Approved Agents For Relapsed/Refractory Multiple Myeloma: Real-World Evidence Based On Electronic Medical Record Data
Learn More
Multiple Myeloma
NA
Active
nct/study# NA / DAH-C-21-USA-003
A Retrospective Chart Review Of Daratumumab In Actively Diagnosed Multiple
Learn More
Multiple Myeloma
Phase I/II
Active
nct/study# NA / LAVA-051
A Phase 1 And 2a Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity And Antitumor Activity Of LAVA-051 In Patients With Relapsed Or Refractory CD1d-Positive Chronic Lymphocytic Leukemia, Multiple Myeloma Or Acute Myeloid Leukemia
Learn More
Multiple Myeloma
Phase I
Active
Multiple Myeloma
Phase 1/2
Active
nct/study# NA / CP-NEXI-002-01
A Phase 1 / 2 Study To Evaluate The Safety And Tolerability Of Adoptively Transferred Autologous T Cells In Patients With Relapsed Refractory Multiple Myeloma
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.